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traditionally focused on RNA sequence elements and their associated splicing factors, but recent
provocative studies point to a key function of chromatin structure and histone modifications in
alternative splicing regulation. These insights suggest that epigenetic regulation determines not
only what parts of the genome are expressed but also how they are spliced.Introduction
The 10th anniversary of the publication of the first draft of the
human genome sequence has sparked a renewed and
expanded interest in alternative pre-mRNA splicing. Alternative
splicing explains how the vast mammalian proteomic complexity
can be achieved with the limited number of genes found in higher
eukaryotes. Current estimates based on deep sequencing
methodologies indicate that more than 90% of human genes
undergo alternative splicing (Croft et al., 2000; Pan et al., 2008;
Wang et al., 2008). Alternative splicing is an integral part of differ-
entiation and developmental programs and contributes to cell
lineage and tissue identity as indicated by the mapping of
more than 22,000 tissue-specific alternative transcript events
in a recent genome-wide sequencing study of tissue-specific
alternative splicing (Wang et al., 2008). The importance of alter-
native splicing is dramatically highlighted by the numerous
diseases that are caused by mutations in either cis-acting RNA
elements or trans-acting protein splicing factors (Caceres and
Kornblihtt, 2002; Cooper et al., 2009). Prominent splicing
diseases include cystic fibrosis, frontotemporal dementia,
Parkinsonism, retinitis pigmentosa, spinal muscular atrophy,
myotonic dystrophy, premature aging, and cancer.
Traditionally, alternative splicing has been thought to be
predominantly regulated by splicing enhancers and silencers
(Chasin, 2007). These short, conserved RNA sequences are
typically 10 nt in length, are located either in exons or introns,
acting either isolated or in clusters, and stimulate (enhancers)
or inhibit (silencers) the use of splice sites through the specific
binding of regulatory proteins such as SR proteins (serine/argi-
nine-rich proteins) or heterogeneous nuclear ribonucleoproteins
(hnRNPs) (Long and Caceres, 2009; Han et al., 2010). In addition,
some silencers, instead of recruiting regulatory proteins, act
by determining pre-mRNA secondary structure that hinders the
recognition of a neighboring splicing enhancer by SR proteins
(Buratti and Baralle, 2004). Disease mutations often affect
the use of constitutive or alternative splice sites by cis-acting16 Cell 144, January 7, 2011 ª2011 Elsevier Inc.mutations that disrupt regulatory RNA sequence elements and
by trans-acting mutations that affect the quality or quantity of
alternative or constitutive splicing factors.
It has long been clear that a full understanding of alternative
splicing regulation will require the molecular characterization
and structural modeling of the spliceosome and the analysis of
RNA regulatory elements. However, the emerging complexity
of alternative splicing regulation makes it apparent that informa-
tion from those approaches will not be sufficient to decipher how
alternative splicing is regulated. Here we discuss mechanisms
and implications of the recently uncovered role of epigenetic
components, such as chromatin structure and histone modifica-
tions, to alternative splicing regulation.
Coupling of Transcription and Splicing
More than 20 years ago, visualization of Drosophila embryo
nascent transcripts by electronmicroscopy showed that splicing
canoccurcotranscriptionally (BeyerandOsheim,1988) (Figure1).
Cotranscriptional splicing was later directly demonstrated for the
human dystrophin gene (Tennyson et al., 1995), where it appears
a very intuitive concept given that transcription of this 2400 kb
gene would take16 hr to complete. Furthermore, a quantitative
studyof the c-Src andfibronectinmRNAs, comparing chromatin-
boundandnucleoplasmicRNA fractions, shows thatmost introns
are excised efficiently in the chromatin-bound fractions, with a
gradient of cotranscriptional splicing efficiency from promoter-
proximal to promoter-distal introns, suggesting cotranscriptional
splicing (Pandya-Jones and Black, 2009). However, cotranscrip-
tionality of splicing is not strict, in the sense that introns are not
necessarily removed in the exact order that they are transcribed
(Attanasio et al., 2003; Bauren and Wieslander, 1994; Kessler
et al., 1993; LeMaire and Thummel, 1990). If that were the case,
the competition between splicing sites that leads to alternative
splicing would be impossible.
Splicing complexes are recruited to all introns and exons
in a time window that begins when the target sequence
Figure 1. Coupling of Transcription and
RNA Processing
RNA polymerase II (green) recruits RNA-process-
ing factors such as the 50 cap-binding complex
(CAP) (yellow), splicing and pre-spliceosome
factors (red), and the polyadenylation complex
(blue) in the context of nucleosome-containing
chromatin. Recruitment of RNA-processing
factors occurs via the RNA Pol II C-terminal
domain (CTD), and much of RNA processing
occurs cotranscriptionally.is transcribed and extends to the moment of splicing catalysis.
For the entire splicing reaction to be cotranscriptional, both
recruitment and catalysis must occur before transcription termi-
nation and transcript release. Alternatively, recruitment of some
or all splicing factors may occur cotranscriptionally, but the
catalysis itself may occur posttranscriptionally. Cotranscrip-
tional pre-mRNA splicing appears to be a general rule for long
mammalian genes. It is unclear how prevalent it is in organisms
with shorter introns, such as yeast, although several studies
support the notion that recruitment of spliceosomal components
is also mostly cotranscriptional in this organism (Gornemann
et al., 2005; Kotovic et al., 2003; Lacadie and Rosbash, 2005;
Tardiff et al., 2006) (Figure 1). Completion of intron removal
appears to be posttranscriptional in most cases, and only in
genes with relatively long downstream exons does it occur prior
to transcript release (Tardiff et al., 2006).
The message from these studies is that cotranscriptional
recruitment of splicing factors is largely preferred, but that co-
transcriptional completion of intron removal is not mandatory
and depends on the specific kinetics of transcription and
splicing. In other words, the selective pressure in favor of
cotranscriptional splicing acts on the association of splicing
factors, which can be viewed as the ‘‘commitment to splice,’’
rather than on the catalysis itself. This might not apply to other
RNA-processing events like capping and cleavage/polyadenyla-
tion (McCracken et al., 1997a, 1997b; Hirose and Manley, 1998;
Maniatis and Reed, 2002; Moore and Proudfoot, 2009), wherein
both the recruitment of the factors and enzymes involved as well
as the catalysis appear to be cotranscriptional.
Although cotranscriptionality of splicing is a prerequisite for
coupling, it does not necessarily mean the two events are
coupled. Cotranscriptionality simply means that splicing takes
place, or is committed to occur, before the nascent RNA is
released from RNA polymerase (Pol) II. Coupling implies that
the transcription and splicing machineries interact with each
other or that the kinetics of one process determines the outcome
of the other. Efficient coordination between transcription and
processing may be a specific feature of RNA Pol II and particu-
larly of the carboxy-terminal domain (CTD) of its catalytic subunit
given that a phosphorylated CTD is required for cotranscriptional
splicing (Bird et al., 2004) (Figure 1). When protein-coding
genes are placed under the control of either RNA Pol I,Cell 1RNA Pol III, or T7 RNA polymerase
promoters, transcription takes place,
but pre-mRNA processing is impaired
and the resulting transcripts are poorlyspliced (Dower and Rosbash, 2002; McCracken et al., 1998;
Sisodia et al., 1987; Smale and Tjian, 1985). In fact, recruitment
of splicing factors to sites of transcription is dependent on RNA
Pol II CTD (Misteli and Spector, 1999) and deletion of the CTD
causes defects in capping, cleavage/polyadenylation, and
splicing of the b-globin transcript (McCracken et al., 1997b)
(Figure 1). Many splicing factors are able to interact with RNA
Pol II in vivo, including almost all known SR proteins and
U1snRNP, and in nuclear extracts that support both transcrip-
tion and splicing in vitro, SR proteins appear to be much more
effective in promoting splicing when the latter is cotranscrip-
tional than when it is posttranscriptional (Das et al., 2007).
However, SR proteins are not delivered to splicing sites by
RNA Pol II alone but rather require ongoing pre-mRNA synthesis
(Sapra et al., 2009), demonstrating that recruitment is not depen-
dent on preassembled SR-RNA Pol II complexes. Coupled
in vitro transcription/splicing assays, although not necessarily
reflecting functional coupling as it would occur in vivo (Lazarev
and Manley, 2007), show that nascent pre-mRNA synthesized
by RNA Pol II is stabilized and efficiently spliced (Hicks et al.,
2006). This is likely because it is immediately and quantitatively
directed into the spliceosome assembly pathway, instead of
being assembled into nonspecific hnRNP complexes, which
are inhibitory for spliceosome assembly (Das et al., 2006).
Strong evidence for functional coupling between transcription
and pre-mRNA processing comes from analyzing how modula-
tion of transcription affects alternative splicing events. It has
been demonstrated that the outcome of alternative splicing is
influenced by the promoter used to drive transcription (Cramer
et al., 1999, 1997; Pagani et al., 2003), by hormone-responsive
elements (Auboeuf et al., 2002), and by recruitment of different
transcription factors or coactivators to the promoter (Auboeuf
et al., 2004a, 2004b; Nogue´s et al., 2002). The effects are not
the trivial consequence of different mRNA levels produced by
each promoter but depend on qualitative properties conferred
by promoters to the transcription/RNA-processing machinery.
Control of Alternative Splicing by Elongation Rate
The standard experimental approach to study splicing mecha-
nisms is by in vitro splicing assays. This methodology employs
in vitro synthesized pre-mRNA substrates in splicing reactions
carried out in cell-free nuclear extracts. Although these44, January 7, 2011 ª2011 Elsevier Inc. 17
conditions are appropriate to identify splicing factors and RNA
intermediates, they are not ideally suited to obtain an accurate
picture of the timing of splicing in relation to the generation of
nascent RNA during transcription. These limitations can be
overcome by in vivo experiments using either transfected
reporter minigenes or endogenous genes as templates for
splicing reactions. It was in fact differences in the behavior of
a splicing event in vivo compared to in vitro that first hinted at
a kinetic role for transcription on splicing. Eperon et al. (1988)
found that the use of an alternative 50 splice site sequestered
within a short stem of RNA secondary structure was determined
by the length of the loop in vivo. Above a threshold loop length,
the alternative site was used despite the potential structure. In
contrast, the alternative site was not used during splicing
in vitro with all lengths of loop tested (Eperon et al., 1988). The
simplest interpretation of these experiments is that the rate of
RNA synthesis affects its secondary structure, which in turn
affects splicing. Further evidence for a kinetic link between tran-
scription and splicing came from experiments in which a MAZ
sequence, which leads to RNA Pol II pausing, inserted into the
tropomyosin gene promoted higher inclusion of tropomyosin
exon 3 (Roberts et al., 1998). Conclusive evidence for a role of
elongation on alternative splicing regulation was the finding
that the nature of the promoter affects alternative splicing
outcome (Cramer et al., 1997, 1999; Kornblihtt, 2005). The orig-
inal observation of this promoter effect involved transient trans-
fection of mammalian cells with reporter minigenes for
the alternatively spliced cassette exon 33 (E33, also referred
to as EDI or EDA) of human fibronectin (FN) under the control
of different RNA Pol II promoters. When transcription of the
minigene was driven by the b-globin promoter, for example,
E33 inclusion levels in the mature mRNA were about 10 times
lower than when transcription was driven from the FN or
cytomegalovirus (CMV) promoter. These effects were not the
consequence of the promoter strength but depended on some
qualitative properties conferred by promoters to the transcrip-
tion/RNA-processing machinery. Two nonexclusive mecha-
nisms could explain the promoter effect: differential promoter
occupation could affect the recruitment of splicing factors by
the transcription machinery (recruitment coupling) or determine
different rates of RNA Pol II elongation (kinetic coupling).
Several lines of evidence support the idea that RNA Pol II
elongation can affect alternative splicing through kinetic
coupling (Figure 2). Replication of reporter plasmids for alterna-
tive splicing in transiently transfected cells greatly stimulated
E33 inclusion. This effect was counteracted by treating the
cells with trichostatin A (TSA), a potent inhibitor of histone deace-
tylation and therefore a chromatin ‘‘opener,’’ allowing for the
possibility that replication conveys a more compact chromatin
structure to the template, thus slowing elongation and leading
to higher E33 inclusion (Kadener et al., 2001). Furthermore, drugs
that inhibit elongation, like DRB (Kadener et al., 2001; Nogue´s
et al., 2002), flavopiridol, or camptothecin (de la Mata et al.,
2010), favor E33 inclusion. On the other hand, activation of tran-
scription by Sp1, a transcription factor that promotes initiation,
has no effect on E33 inclusion, whereas activation by VP16,
a factor that promotes both initiation and elongation, decreases
E33 inclusion (Nogue´s et al., 2002). The strongest evidence for18 Cell 144, January 7, 2011 ª2011 Elsevier Inc.a kinetic role of RNA Pol II elongation comes, however, from a
slow mutant of RNA Pol II, which increases E33 inclusion in
human cells (de la Mata et al., 2003). Interestingly, the homolo-
gous mutation in Drosophila (C4 Pol II) is viable but shows
changes in the alternative splicing pattern of ultrabithorax (Ubx)
mRNA that are consistent with the only conspicuous phenotype
of the C4 flies, which is an enlargement of the halteres that
resembles the Ubx mutants. Why slowing elongation would
only affect the Ubx gene is not known, but a clue might be that
this gene has the longest introns in Drosophila (17 and 50 kb)
flanking the alternative exons affected in the C4 genotype, sug-
gesting that elongation becomes more critical when introns are
long. Similar effects of elongation on splicing have been reported
in yeast on an artificially created alternative exonwhen transcrip-
tion is carried out by a slow RNA Pol II mutant or when the
elongation factor TFIIS is mutated (Howe et al., 2003). Finally,
DNA-damage signaling following irradiation of cells with UV light
affects alternative splicing of fibronectin, caspase 9, Bcl-x, and
other human genes as a consequence of the inhibition of RNA
Pol II elongation caused by UV-dependent hyperphosphoryla-
tion of the CTD (Mun˜oz et al., 2009).
These data support a ‘‘first come, first served’’ model for regu-
lation of alternative splicing (Aebi and Weissmann, 1987)
(Figure 2). In one version of this model, slow elongation favors
removal of the intron upstream of an alternative cassette exon
before removal of the downstream intron. In an alternative
version, slow elongation favors recruitment of splicing factors
to the upstream intron before the downstream intron is synthe-
sized, which in turn would promote exon inclusion. Once
commitment is achieved, the order of intron removal becomes
irrelevant (Figure 2). The latter model is supported by recent
evidence showing that there is a preferential removal of the intron
downstream of the fibronectin cassette exon 33 before the
upstream intron has been removed (de la Mata et al., 2010).
Most importantly, whereas cis-actingmutations and trans-acting
factors that upregulate E33 inclusion act by changing the relative
order of intron removal, reduction of elongation, which also
causes higher E33 inclusion, does not affect the order of intron
removal, suggesting that slow elongation favors commitment
to exon inclusion during spliceosome assembly (de la Mata
et al., 2010). According to this, ‘‘first served’’ would not be equiv-
alent to ‘‘first excised’’ but to ‘‘first committed,’’ in agreement
with the observed preferential cotranscriptionality of spliceo-
some recruitment rather than catalysis.
Chromatin and Histone Modifications as Regulators
of Alternative Splicing
As we delve deeper into the regulation of alternative splicing, it is
becoming clear that control of splice site choice is far more
complex than anticipated. Neither RNA-binding elements nor
control by RNA Pol II elongation rate appear sufficient to fully
explain the faithful regulation of alternative splicing. RNA-binding
motifs are not always conserved between genes, and even when
motifs are transcribed that contain errors, they often still accu-
rately recruit the appropriate set of splicing factors to the exon
(Fox-Walsh and Hertel, 2009). Similarly, although RNA Pol II
elongation rate affects splicing outcome in different scenarios
(de la Mata et al., 2003; Mun˜oz et al., 2009), it remains unclear
Figure 2. The RNA Polymerase II Kinetic
Model for Alternative Splicing
Rapid elongation of RNA polymerase II (Pol II)
leads to simultaneous availability to the splicing
machinery of a weak (red) and a strong (blue)
splice site, which compete for the recruitment of
splicing factors (purple, blue, and green ovals)
resulting in skipping of the weaker exon (orange
rectangle). Pausing or slowing down of the RNA
Pol II favors the recruitment of the splicing
machinery to the first transcribed, weaker exon
leading to its subsequent inclusion in a ‘‘first
served, first committed’’ model.to what extent RNA pol II processivity can be modulated in vivo,
how RNA Pol II elongation rate is controlled, and whether regu-
lation of alternative splicing patterns through RNA Pol II kinetics
is a commonly used mechanism in vivo. These considerations
indicate that other mechanisms contribute to the control of alter-
native splicing. A major recent discovery is that chromatin struc-
ture and epigenetic histone modifications act as key regulators
of alternative splicing.
Chromatin Structure
The first, albeit indirect, evidence that chromatin structure partic-
ipates in the regulation of alternative splicing was the finding that
fibronectin exon E33 inclusion was sensitive to replication-medi-
ated chromatinization status of the plasmid and to the histone
deacetylase inhibitor TSA (Kadener et al., 2001; Nogue´s et al.,
2002). Further support came from the study of hormone-sensi-
tive promoters that were tested for their effects on alternative
splicing of a CD44 reporter gene (Auboeuf et al., 2002). Treat-
ment with different steroid hormones induced changes in
CD44 alternative splicing only if the minigene was under the
control of the appropriate steroid-dependent promoter and in
the presence of the specific hormone receptor, even though
strong constitutive promoters were used (Auboeuf et al., 2002).
Importantly, the effect on splicing was not due to changes in
transcription rate, the density of the RNA Pol II, the strength
of the promoter, or saturation of the splicing machinery but
appeared mediated by the recruitment of specific hormoneCell 1receptor coregulators that remodeled
chromatin (Auboeuf et al., 2002). Along
the same lines, the histone acetyltransfer-
ase Gcn5 in yeast (Gunderson and
Johnson, 2009) and STAGA in humans
(Martinez et al., 2001) physically interact
with U2 snRNPs, and the histone arginine
methyltransferase CARM1 interacts with
U1 snRNP proteins (Cheng et al., 2007;
Ohkura et al., 2005), suggesting a role of
chromatin complexes in facilitating the
correct assembly of the pre-spliceosome
on pre-mRNA. These effects are inde-
pendent of elongation rate, arguing for
a more direct role for chromatin structure
on splicing factor recruitment (Gunderson
and Johnson, 2009). Furthermore, chro-
matin remodelers of the SWI/SNF family
in humans and Drosophila also have aneffect on alternative splicing that is independent of their
ATPase remodeling activity and dependent on physical interac-
tion and recruitment of snRNPs U1 and U5 (Batsche et al., 2006;
Tyagi et al., 2009).
The recent advent of methods to map chromatin structure at
a genome-wide scale further supports a role for chromatin
structure in alternative splicing. Genome-wide mapping of
nucleosome positioning by micrococcal nuclease (MNase)
digestion from various species has shown that nucleosomes
are positioned nonrandomly along genes and are particularly
enriched at intron-exon junctions, thus marking exons (Ander-
sson et al., 2009; Chodavarapu et al., 2010; Dhami et al., 2010;
Kolasinska-Zwierz et al., 2009; Nahkuri et al., 2009; Ponts
et al., 2008; Schwartz et al., 2009; Spies et al., 2009; Tilgner
et al., 2009). Nucleosomes, defined as a stretch of 147 bp
of DNA wrapped around an octamer of histone proteins, are
structural units of chromatin that determine chromatin confor-
mation and compaction. Intriguingly, the average size of
a mammalian exon is similar to the length of DNA wrapped
around a nucleosome, possibly pointing to a protective role of
the nucleosome and a function in exon definition (Schwartz
et al., 2009; Tilgner et al., 2009). Indeed, nucleosome enrichment
around exons is conserved in evolution from plants to mammals
and found both in somatic cells and gametes (Nahkuri et al.,
2009), suggesting an essential role of nucleosome positioning
in exon definition. The marking of exons by nucleosomes may44, January 7, 2011 ª2011 Elsevier Inc. 19
play a role in splicing regulation given that they are positioned
irrespective of gene expression levels (Andersson et al., 2009;
Tilgner et al., 2009). Moreover, isolated exons in the middle of
long introns display higher nucleosome positioning than clus-
tered exons separated by small introns (Spies et al., 2009),
whereas pseudo-exons, which are nonincluded intronic
sequences flanked by strong splice sites, are depleted of nucle-
osomes (Tilgner et al., 2009). More tellingly, included alterna-
tively spliced exons are more highly enriched in nucleosomes
than excluded ones (Schwartz et al., 2009) and nucleosome
density varies according to splice site strength with stronger
positioning at exons defined by weaker splice elements (Spies
et al., 2009; Tilgner et al., 2009), arguing for a role of nucleosome
positioning not only in exon definition but also in the regulation of
splicing.
Along with nucleosomes, RNA Pol II is also differentially distrib-
uted along genes in plants and humans with preferential accumu-
lation at exons relative to introns (Brodsky et al., 2005; Chodavar-
apu et al., 2010; Schwartz et al., 2009). Nucleosomes have been
shown to behave as barriers that can locally modulate RNA Pol
II density by inducing its pausing (Hodges et al., 2009a). Together
with theability ofRNAPol II to interactwith histonemodifiers, such
as the histone 3 lysine 36 (H3K36) methyltransferase Set2 (Xiao
et al., 2003), and to recruit splicing regulators, such asSRproteins
or U2 snRNP subunits (de laMata andKornblihtt, 2006; Listerman
et al., 2006), nucleosome positioningmay bemodulating RNAPol
II density at exons and therefore splicing efficiency. In agreement,
RNA Pol II is more highly enriched at alternatively spliced exons
than at constitutive ones (Brodskyet al., 2005). Furthermore,over-
expression of the ATPase-dependent chromatin-remodeling
complex SWI/SNF subunit Brm in human cells induces accumu-
lation of phospho-RNAPol II in a central block of alternative exons
of the CD44 gene and causes increased inclusion of these exons
into mature mRNA (Batsche et al., 2006).
Although these observations point to a role of nucleosome
positioning and chromatin structure in alternative splicing regu-
lation, a caveat of these studies is their correlative nature.
Directed experiments to test the effect on alternative splice site
selection upon modulation of chromatin and nucleosome posi-
tioning in a targeted fashion will be required to distinguish direct
from indirect effects on alternative splicing.
Histone Modifications in Alternative Splicing Regulation
Histone modifications are emerging as major regulators of
alternative splicing. Genome-wide analysis of the distribution
of 42 histone modifications reveals that histone marks are non-
randomly distributed in the genome and that several modifica-
tions are enriched specifically in exons relative to their flanking
intronic regions (Kolasinska-Zwierz et al., 2009; Spies et al.,
2009; Andersson et al., 2009; Schwartz et al., 2009). Even though
the enrichment of many histone modifications is a reflection of
the higher density of nucleosomes at exons, some histonemarks
such as trimethylated H3K36 (H3K36me3), H3K4me3, and
H3K27me2 are elevated even after normalization for nucleosome
enrichment, whereas others, such as H3K9me3, are depleted
(Dhami et al., 2010; Spies et al., 2009). In support of a splicing
regulatory role of histone marks, histone modification levels do
not correlate with transcriptional activity (Spies et al., 2009)
and in active genes the transcription-associated H3K36me320 Cell 144, January 7, 2011 ª2011 Elsevier Inc.modification is less prominently enriched in alternatively spliced
exons than in constitutive exons (Andersson et al., 2009; Kola-
sinska-Zwierz et al., 2009).
An additional indication for a role of histone modifications in
alternative splicing is the observation that treatment of cells
with the histone deacetylase inhibitor TSA induces skipping
of the alternatively spliced fibronectin E33 and the neural cell
adhesion molecule (NCAM) exon 18 (Nogue´s et al., 2002; Allo´
et al., 2009; Schor et al., 2009). In a more physiological context,
depolarization of human neuronal cells increases H3K9 acetyla-
tion and H3K36 methylation locally around the alternatively
spliced exon 18 of NCAM and induces exon skipping (Schor
et al., 2009). Noticeably, no changes in histone acetylation are
observed at the NCAM promoter. This reversible effect may be
due to an intragenic and local modulation of the RNA Pol II
elongation rate (Schor et al., 2009). Furthermore, targeting of
an intronic sequence upstream of the alternatively spliced E33
of fibronectin with small-interfering RNAs induces local hetero-
chromatinization and increased E33 inclusion without affecting
general transcription levels (Allo´ et al., 2009). Consistently,
inhibition of histone deacetylation, DNA methylation, H3K9
methylation, and downregulation of heterochromatin protein
1a (HP1a) abolishes the siRNA-mediated effect on exon E33
splicing (Allo´ et al., 2009), suggesting a role of these modifica-
tions in alternative splicing regulation.
Further evidence for histone-mediated alternative splicing
control comes from observations on the human fibroblast growth
factor receptor 2 (FGFR2) gene. FGFR2 is alternatively spliced
into two mutually exclusive and highly tissue-specific isoforms,
FGFR2-IIIb and -IIIc. According to the pattern of splicing, the
gene is enriched in a particular subset of histone modifications
with H3K36me3 and H3K4me1 accumulating along the alterna-
tively spliced region in mesenchymal cells, where exon IIIc is
included, and H3K27me3 and H3K4me3 enriched in epithelial
cells, where exon IIIb is used (Luco et al., 2010). Importantly,
modulation of H3K36me3 or H3K4me3 levels by overexpression
or downregulation of their respective histone methyltransferases
changes the tissue-specific alternative splicing pattern in
a predictable fashion (Luco et al., 2010). Taken together, these
observations suggest that localized changes in chromatin
conformation and histonemodification signatures along an alter-
natively spliced region can change splicing outcome.
Although there is no experimental evidence at present, it is
possible that DNA methylation may also, directly or indirectly
via histone modifications, affect splice site choice. DNA methyl-
ation patterns correlate better with histone methylation patterns
than with genome sequence context (Meissner et al., 2008).
Mapping in plants and human cells of DNA methylation levels
by single-molecule whole-genome bisulfate sequencing reveals
that DNA methylation is also nonrandomly distributed along the
genome, specifically marking exons (Chodavarapu et al., 2010;
Hodges et al., 2009b) and correlating well with H3K36me3 but
inversely correlating with H3K4me2 levels (Hodges et al., 2009b).
These observations point to a role for epigenetic modifications
in the regulation of alternative splicing, and this regulation
may involve the modulation of RNA Pol II elongation rate. How-
ever, an additional mechanism has recently emerged involving
direct physical crosstalk between chromatin and the splicing
Figure 3. The Chromatin-Adaptor Model of
Alternative Splicing
Histone modifications along the gene determine
the binding of an adaptor protein that reads
specific histone marks and in turn recruits splicing
factors. In the case of exons whose alternative
splicing is dependent on polypyrimidine tract-
binding protein (PTB) splicing factor, high levels of
trimethylated histone 3 lysine 36 (H3K36me3, red)
attract the chromatin-binding factor MRG15 that
acts as an adaptor protein and by protein-protein
interaction helps to recruit PTB to its weaker
binding site inducing exon skipping. If the PTB-
dependent gene is hypermethylated in H3K4me3
(blue), MRG15 does not accumulate along the
gene, and PTB is not recruited to its target pre-
mRNA, thus favoring exon inclusion.machinery via an adaptor complex (Sims et al., 2007; Luco et al.,
2010) (Figure 3).
Chromatin-Splicing Adaptor Systems
A hint toward a direct role for histone modifications in alternative
splicing regulation came from comparative mapping of a set of
histone modifications along several genes whose alternative
splicing is dependent on the polypyrimidine tract-binding protein
(PTB) splicing factor. These studies revealed a strong correlation
between several histone modifications across the alternatively
spliced regions and splicing outcome (Luco et al., 2010). PTB-
dependent genes were found to be enriched in H3K36me3 and
depleted in H3K4me3 in the alternatively spliced regions. Modu-
lation of these histone marks was sufficient to switch the pattern
of PTB-dependent exon inclusion (Luco et al., 2010). The molec-
ular mechanism by which H3K36me3 acts in this case does not
appear to involve modulation of RNA Pol II elongation rate but
rather the creation of a platform on chromatin for the recruitment
of PTB to the nascent RNA (Figure 3) (Luco et al., 2010). This
occurs via an adaptor protein, MRG15, that specifically binds
to H3K36me3. The high levels of H3K36me3 along the alterna-
tively spliced region of the gene attract MRG15, which in turn
interacts with PTB recruiting it to the nascent RNA (Luco et al.,
2010). In contrast, in cell types where H3K36me3 levels are
low, the splicing repressor PTB is only poorly recruited to the
newly forming RNA as a consequence favoring inclusion of the
PTB-dependent exon (Luco et al., 2010) (Figure 3). H3K36me3,
MRG15, and PTB thus establish a chromatin-splicing adaptor
system. In line with this interpretation, increasing H3K36me3
levels in the absence of theMRG15 adaptor protein has no effect
on FGFR2 alternative splicing (Luco et al., 2010).
Although histone modifications clearly play a direct role in
splicing regulation in this system, interestingly, the histonemodi-
fications do not appear to be the sole determinant of splicing
outcome; they rather act as a modifier. Genome-wide analysisCell 1of PTB-dependent alternative splicing
patterns reveal that the splicing events
that are most sensitive to changes in
histone modifications rely on weak PTB-
binding sites whereas alternative splicingevents involving strong PTB-binding sites are not dependent on
H3K36me3, suggesting that epigenetic modifications act in
concert with RNA-binding elements to strengthen their effect
(Luco et al., 2010).
There is reason to believe that the combination of H3K36me3/
MRG15/PTB is not the only chromatin-splicing adaptor system
in mammalian cells (Figure 4). It is known that H3K4me3 levels
play a role in the recruitment of the early spliceosome to human
cyclin D1 pre-mRNA via binding of the chromatin-adaptor
protein CHD1 (Sims et al., 2007). CHD1 contains a chromodo-
main that specifically recognizes H3K4me3 and interacts with
components of the U2 snRNP complex but not U1 snRNP
(Sims et al., 2007). Consistent with a role in splicing regulation,
downregulation of H3K4me3 or CHD1 alters the efficiency of
pre-mRNA splicing and reduces association of splicing factor
3a (SF3a) subcomplexes and U2 snRNP with pre-mRNA
in vitro and in vivo (Sims et al., 2007). Interestingly, CHD1 is
also a component of the histone acetyltransferase SAGA
complex (Pray-Grant et al., 2005) in which Gcn5, which binds
to acetylated H3 (Li and Shogren-Knaak, 2009), also interacts
and recruits U2 snRNP components to the exon (Gunderson
and Johnson, 2009; Figure 4). Another example of a possible
chromatin-splicing adaptor system is H3K9 trimethylation
and HP1 proteins, which appear to recruit hnRNPs in Drosophila
(Piacentini et al., 2009; Figure 4). Mass spectrometry analysis
of proteins that bind to H3K9me identified the chromatin-binding
protein HP1a/b and the splicing factors SRp20 and ASF/SF2
as interaction partners (Loomis et al., 2009). Coimmunopre-
cipitation experiments confirmed that HP1b interacts with
ASF/SF2 in humans (Loomis et al., 2009) and HP1a with
hnRNP proteins in Drosophila (Piacentini et al., 2009). These
results point to a possible role for H3K9me3 in the regulation
of recruitment of splicing factors mediated by the chromatin-
adaptor protein HP1, although their functional relevance to
splice site selection remains to be determined (Figure 4). Finally,44, January 7, 2011 ª2011 Elsevier Inc. 21
Figure 4. Chromatin-Adaptor Complexes
Several histone modification-binding chromatin
proteins interact with splicing factors (Luco et al.,
2010; Sims et al., 2007; Gunderson and Johnson,
2009; Piacentini et al., 2009; Loomis et al., 2009).other combinations of interacting histone modifications, chro-
matin-binding proteins, and splicing factors may exist, possibly
constituting a complex network of communication between
chromatin and RNA. Genome-wide mapping of histone modifi-
cations and comparison to alternative splicing patterns should
reveal such additional chromatin-splicing adaptor systems.
An IntegratedModel for Alternative Splice Site Selection
Regulation of alternative splicing has longbeen thought to involve
mostly cis-acting RNA elements. However, the picture becomes
far more complex when one considers that RNA processing is
coupled to transcription (Figure 5). The ultimate driving factor in
determining splicing outcome is obviously the recruitment of
splicing regulators to the target RNA (Barash et al., 2010).
However,whenandwhich factors are recruited is not only depen-
dent on the combination of RNA motifs, the tissue- or develop-
mental-specific pattern of expression of the splicing factors, or
their posttranslational modifications as thought until now, but is
also greatly influenced by chromatin architecture and histoneFigure 5. An Integrated Model for the Regulation of Alternative
Splicing
Alternative splicing patterns are determined by a combination of parameters
including cis-acting RNA regulatory elements and RNA secondary structures
(highlighted in orange) together with transcriptional and chromatin properties
(highlighted in blue) thatmodulate the recruitment of splicing factors to the pre-
mRNA.
22 Cell 144, January 7, 2011 ª2011 Elsevier Inc.modifications. The contribution of tran-
scription regulators and histonemodifiers
to splicing regulation is likely 2-fold: On
the one hand, they remodel and open
chromatin for the recruitment of elonga-
tion factors that activate RNA Pol II elon-
gation kinetics. On the other hand, the
positioning of nucleosomes along exons,
plus the enrichment in particular subsetsof histone modifications, may modulate the recruitment of
splicing regulators (Kolasinska-Zwierz et al., 2009; Schwartz
et al., 2009; Spies et al., 2009). This could occur either through
pausing of RNA Pol II, which favors the formation of the spliceo-
some by protein-protein interactions (de la Mata and Kornblihtt,
2006; Listerman et al., 2006), or through specific recruitment of
splicing factors via adaptor complexes to weak RNA-binding
sites (Luco et al., 2010; Sims et al., 2007; Gunderson and John-
son, 2009; Piacentini et al., 2009). These observations suggest
an integrated model for the regulation of transcription and
splicing in which the factors involved in the transcription control
and chromatin maintenance also contribute to the recruitment
and assembly of the spliceosome (Figure 5).
The Role of Chromatin in Other RNA-Processing Events
The role of chromatin and histone modifications likely goes
beyond alternative splicing. There are some indications that
other RNA-processing events are similarly modulated by chro-
matin and epigenetic modifications.
In S. cerevisiae, the 30 region near the polyadenylation site is
depleted of nucleosomes (Mavrich et al., 2008), and in human
T cells nucleosome density dips noticeably within 200 nt of the
canonical polyadenylation signal (Spies et al., 2009). Functional
relevance for nucleosome density in polyadenylation is suggested
by the fact that in genes containingmultiple polyadenylation sites,
the most highly used site preferentially falls within a nucleosome-
depleted region (Spies et al., 2009). Bioinformatic analysis also
suggests that nucleosomeaffinity is reduced near highly usedpol-
yadenylation sites but markedly increases just downstream of
them (Spies et al., 2009). Altered nucleosome density may affect
RNAPol II elongation kinetics,which is known toaffect polyadeny-
lation, or the recruitment of the polyadenylation machinery to the
nascent transcript (McCracken et al., 1997b).
Further evidence for a role of chromatin in RNA processing
comes from the surprising finding in Drosophila that several
histone variants including the core histones H3.3A, H3.3B,
H2a.V, and the H3-histone chaperone Asf1 are required for pro-
cessing of the metazoan histone RNAs (Marzluff et al., 2008).
Histone RNAs are unique in that they lack introns and are not pol-
yadenylated and their 30 ends are processed in a single step by
formation of a 30 stem-loop structure (Wagner et al., 2007). Loss
of H2a.V, the functional ortholog of human H2A.X and H2A.Z,
Figure 6. The Epigenetics of Alternative Splicing
The combination of histone modifications along a gene establishes and maintains tissue-specific transcription patterns (left panel), as well as heritable tissue-
specific alternative splicing patterns (right panel).results in readthrough and failure to process histone pre-
mRNAs. The reason appears to be failure to recruit histone
RNA-processing factors to nascent histone RNAs (Marzluff
et al., 2008). Although it is currently unknown how H2a.V affects
processing factor recruitment, one intriguing possibility is that
the altered chromatin structure at the histone loci interferes
with the proper assembly of histone RNA-processing machinery,
thus decreasing RNA-processing efficiency.
Another RNA metabolic event that appears to be influenced by
chromatin is RNA degradation. In an attempt to uncover novel
functions for the S. pombe histone variant H2A.Z, Grewal and
colleagues noted that absence of H2A.Z leads to an increase in
antisense transcripts in 5%–8%of loci, whereas the level of sense
transcripts is onlymodestly affected (Zofall et al., 2009). The accu-
mulating antisense messages were mostly readthrough tran-
scripts, and run-on experiments indicated that the elevated tran-
script levels are not due to increased transcription but are the
consequence of failed degradation by the exosome (Zofall et al.,
2009). In support of these conclusions, deletion of the exosome
subunit rrp6 resulted in an antisense RNA profile similar to that
observed upon loss of H2A.Z. These observations point to a role
of chromatin structure in antisense RNA degradation by the exo-
some. The absence of H2A.Z may directly, or indirectly through
loading of factors involved in maintaining chromatin structure,
change chromatin conformation, which interferes with RNA Pol II
progression, leading to RNA Pol II stalling and consequent degra-
dation of transcripts. However this view is not fully consistent with
the observation of readthrough transcripts generated in the
absence of H2A.Z. Alternatively, H2A.Zmay play a role in commu-
nicating to an RNA Pol II-associated exosome that readthrough
transcripts have been generated. Intriguing questions are whether
similar mechanisms are also at play in higher eukaryotes and
whether H2A.Z, other histone variants, and/or chromatin structure
in general play a more universal role in stability and controlled
degradation of regular sense transcripts.Chromatin as a Memory of Alternative Splicing Patterns
Many alternative splicing events occur in a tissue- and/or cell
type-specific fashion. How tissue- and cell type-specific alterna-
tive splicing patterns are established, propagated, and main-
tained is only poorly understood. One mechanism involves the
tissue-specific expression of alternative splicing regulators, the
classical example being the neuron-specific splicing factor
NOVA-1/2, which regulates an extensive network of alternatively
spliced target genes (Ule et al., 2005). However, given the scar-
city of dedicated alternative splicing master controllers, such
regulation is likely the exception rather than the rule.
Cell- and tissue-specific alternative splicing patterns are obvi-
ously not determined solely by RNA-binding motifs, as they are
present identically in all cell types. Although cell- and tissue-
specific differences in expression of constitutive splicing factors
havebeen reported (Hanamuraetal., 1998), it isdifficult toenvision
how global changes in abundance of general splicing factors in
a cell type or tissue can account for the intricate regulation of indi-
vidual exons, some of which need to be included, some skipped,
and others requiring activation of cryptic splice sites, even within
the same gene. Given the realization that chromatin structure
and histone modifications can affect alternative splicing, it is
attractive to speculate that, in analogy to the histone indexing
mechanisms used to specify which genes are expressed and
which ones are silenced, a histone-based system may also
encode information that specifies alternative splicing patterns in
cell types and tissues (Figure 6). Such a system may involve
marking of chromatin stretches encoding alternatively spliced
regions by histone modifications either to alter RNA Pol II elonga-
tion rate locally as the polymerase passes through or to recruit
splicing factors via adaptor complexes. An advantage of such
a histone-based alternative splicing regulatory system is that it
would provide an epigenetic memory for splicing decisions that
could be passed on during proliferation of a cell population and
could be modified during differentiation without the requirementCell 144, January 7, 2011 ª2011 Elsevier Inc. 23
to establish a new set of alternative splicing rules at each step of
differentiation. Obviously, an epigenetic alternative splicing
memory would still require the proper expression of splicing
factors, a process that itself may be controlled by epigenetic
mechanisms. Regardless of mechanisms, it appears that epige-
netic regulation is not limited to controlling what regions of the
genome are expressed, but also how they are spliced.
Conclusions and Outlook
The realization that chromatin and histone modifications
contribute to RNA processing, particularly alternative pre-
mRNA splicing, has recently inspired many new avenues of
investigation—but at the same time it raisesmany key questions.
At this point, we do not even have a comprehensive view of how
histone modifications relate to alternative splicing outcome. For
that, histone modifications must be comprehensively mapped
across the genome in as many cell types and tissues as possible
and compared to genome-wide alternative splicing patterns.
This information should be readily forthcoming from genome-
wide histone modification mapping projects and the parallel
characterization of the transcriptome in those systems by deep
sequencing. These approaches will also answer the fundamental
question of whether histone modifications that have been
implicated in alternative splicing regulation act alone or in a
combinatorial fashion with other epigenetic marks. Systematic
genome-wide studies should also resolve the issue of how
extensive the regulation of alternative splicing by histone modifi-
cations is. Are all alternative splicing events sensitive to histone
modifications, or is only a subset of exons affected? If so, what
are their characteristics? An intriguing extension of these consid-
erations is the possibility that noncoding RNAs might play a role
in alternative splicing regulation (Kishore and Stamm, 2006;
Khanna and Stamm, 2010). ncRNAs are now known to be
involved in heterochromatin structure, and it is possible that
some ncRNAs are specifically transcribed and associate with
alternatively spliced regions of genes.
Having established a role for histone modifications in alterna-
tive splicing, and given the intimate linkage between transcrip-
tion and RNA processing, the question of whether splicing in
turn also affects histone modifications must be asked. It is
possible that in the same way histone modifications modulate
recruitment of splicing factors, splicing regulators also modulate
the recruitment of histone modifiers and chromatin remodelers
to the nucleosomes regulating chromatin conformation in a feed-
back mechanism. In support of such crosstalk, inhibition of
splicing abolishes transcription and splicing factors stimulate
elongation (O’Keefe et al., 1994; Fong and Zhou, 2001; Lin
et al., 2008), suggesting that transcription, chromatin, and
splicing are intimately dependent on each other. Considering
the still preliminary but tantalizing evidence that chromatin may
also affect other RNA-processing events, it will be important to
probe in more detail the effect of chromatin on 30 processing,
RNA stability, and other RNA-processing steps.
Finally, we must consider the possible physiological and path-
ological consequences and opportunities of histone-mediated
RNA-processing effects. First and foremost, it will be important
to determine whether histone modification effects on RNA pro-
cessing are heritable and therefore truly epigenetic or whether24 Cell 144, January 7, 2011 ª2011 Elsevier Inc.they are merely transient modulators. To address this question,
we will have to systematically analyze changes in RNA-process-
ing patterns during differentiation and development and
compare them to histone modification fingerprints of cells and
tissues. We should also comprehensively probe for aberrant
RNA processing in diseases caused by epigenetic defects. In
addition, we may have to reconsider the expected effects of
drugs targeting epigenetic mechanisms such as the clinically
used histone deacetylase and DNAmethyltransferase inhibitors,
and we might want to think about designing new drugs targeting
chromatin for the treatment of splicing diseases. Clearly the
emerging role of epigenetics in RNA processing provides many
new challenges, and even more opportunities.
ACKNOWLEDGMENTS
This work was supported by grants to A.R.K. from the Agencia Nacional de
Promocio´n de Ciencia y Tecnologı´a of Argentina, the Universidad de Buenos
Aires, and the European Alternative Splicing Network (EURASNET). I.E.S. is
a recipient of a postdoctoral fellowships, and A.R.K. is a career investigator
from the Consejo Nacional de Investigaciones Cientı´ficas y Te´cnicas of
Argentina (CONICET). A.R.K. is an international research scholar of the
Howard Hughes Medical Institute. Work in the Misteli laboratory is supported
by the Intramural Research Program of the National Institutes of Health (NIH),
NCI, Center for Cancer Research.REFERENCES
Aebi, M., and Weissmann, C. (1987). Precision and orderliness in splicing.
Trends Genet. 3, 102–107.
Allo´, M., Buggiano, V., Fededa, J.P., Petrillo, E., Schor, I., de la Mata, M.,
Agirre, E., Plass, M., Eyras, E., Abou Elela, S., et al. (2009). Control of alterna-
tive splicing through siRNA-mediated transcriptional gene silencing.
Nat. Struct. Mol. Biol. 16, 717–724.
Andersson, R., Enroth, S., Rada-Iglesias, A., Wadelius, C., and Komorowski, J.
(2009). Nucleosomes are well positioned in exons and carry characteristic
histone modifications. Genome Res. 19, 1732–1741.
Attanasio, C., David, A., and Neerman-Arbez, M. (2003). Outcome of donor
splice site mutations accounting for congenital afibrinogenemia reflects order
of intron removal in the fibrinogen alpha gene (FGA). Blood 101, 1851–1856.
Auboeuf, D., Honig, A., Berget, S.M., and O’Malley, B.W. (2002). Coordinate
regulation of transcription and splicing by steroid receptor coregulators.
Science 298, 416–419.
Auboeuf, D., Dowhan, D.H., Kang, Y.K., Larkin, K., Lee, J.W., Berget, S.M., and
O’Malley, B.W. (2004a). Differential recruitment of nuclear receptor coactiva-
tors may determine alternative RNA splice site choice in target genes. Proc.
Natl. Acad. Sci. USA 101, 2270–2274.
Auboeuf, D., Dowhan, D.H., Li, X., Larkin, K., Ko, L., Berget, S.M., and O’Mal-
ley, B.W. (2004b). CoAA, a nuclear receptor coactivator protein at the interface
of transcriptional coactivation and RNA splicing. Mol. Cell. Biol. 24, 442–453.
Barash, Y., Calarco, J.A., Gao, W.J., Pan, Q., Wang, X.C., Shai, O., Blencowe,
B.J., and Frey, B.J. (2010). Deciphering the splicing code. Nature 465, 53–59.
Batsche, E., Yaniv, M., and Muchardt, C. (2006). The human SWI/SNF subunit
Brm is a regulator of alternative splicing. Nat. Struct. Mol. Biol. 13, 22–29.
Bauren, G., and Wieslander, L. (1994). Splicing of Balbiani ring 1 gene pre-
mRNA occurs simultaneously with transcription. Cell 76, 183–192.
Beyer, A.L., and Osheim, Y.N. (1988). Splice site selection, rate of splicing,
and alternative splicing on nascent transcripts. Genes Dev. 2, 754–765.
Bird, G., Zorio, D.A., and Bentley, D.L. (2004). RNA polymerase II carboxy-
terminal domain phosphorylation is required for cotranscriptional pre-mRNA
splicing and 30-end formation. Mol. Cell. Biol. 24, 8963–8969.
Brodsky, A.S., Meyer, C.A., Swinburne, I.A., Giles, H., Keenan, B.J., Liu, X.L.S.,
Fox, E.A., and Silver, P.A. (2005). Genomic mapping of RNA polymerase II
reveals sitesofco-transcriptional regulation inhumancells.GenomeBiol.6,R64.
Buratti, E., and Baralle, F.E. (2004). Influence of RNA secondary structure on
the pre-mRNA splicing process. Mol. Cell. Biol. 24, 10505–10514.
Caceres, J.F., and Kornblihtt, A.R. (2002). Alternative splicing: multiple control
mechanisms and involvement in human disease. Trends Genet. 18, 186–193.
Chasin, L.A. (2007). Searching for splicing motifs. Adv. Exp. Med. Biol. 623,
85–106.
Cheng, D.H., Cote, J., Shaaban, S., and Bedford, M.T. (2007). The arginine
methyltransferase CARM1 regulates the coupling of transcription and mRNA
processing. Mol. Cell 25, 71–83.
Chodavarapu, R.K., Feng, S., Bernatavichute, Y.V., Chen, P.Y., Stroud, H., Yu,
Y., Hetzel, J.A., Kuo, F., Kim, J., Cokus, S.J., et al. (2010). Relationship
between nucleosome positioning and DNA methylation. Nature 15, 388–392.
Cooper, T.A., Wan, L., and Dreyfuss, G. (2009). RNA and disease. Cell 136,
777–793.
Cramer, P., Pesce, C.G., Baralle, F.E., and Kornblihtt, A.R. (1997). Functional
association between promoter structure and transcript alternative splicing.
Proc. Natl. Acad. Sci. USA 94, 11456–11460.
Cramer, P., Caceres, J.F., Cazalla, D., Kadener, S., Muro, A.F., Baralle, F.E.,
and Kornblihtt, A.R. (1999). Coupling of transcription with alternative splicing:
RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing
enhancer. Mol. Cell 4, 251–258.
Croft, L., Schandorff, S., Clark, F., Burrage, K., Arctander, P., and Mattick, J.S.
(2000). ISIS, the intron information system, reveals the high frequency of alter-
native splicing in the human genome. Nat. Genet. 24, 340–341.
Das, R., Dufu, K., Romney, B., Feldt, M., Elenko, M., and Reed, R. (2006).
Functional coupling of RNAP II transcription to spliceosome assembly. Genes
Dev. 20, 1100–1109.
Das, R., Yu, J., Zhang, Z., Gygi, M.P., Krainer, A.R., Gygi, S.P., and Reed, R.
(2007). SR proteins function in coupling RNAP II transcription to pre-mRNA
splicing. Mol. Cell 26, 867–881.
de la Mata, M., Alonso, C.R., Kadener, S., Fededa, J.P., Blaustein, M., Pelisch,
F., Cramer, P., Bentley, D., and Kornblihtt, A.R. (2003). A slowRNA polymerase
II affects alternative splicing in vivo. Mol. Cell 12, 525–532.
de la Mata, M., and Kornblihtt, A.R. (2006). RNA polymerase II C-terminal
domain mediates regulation of alternative splicing by SRp20. Nat. Struct.
Mol. Biol. 13, 973–980.
de la Mata, M., Lafaille, C., and Kornblihtt, A.R. (2010). First come, first served
revisited: factors affecting the same alternative splicing event have different
effects on the relative rates of intron removal. RNA 16, 904–912.
Dhami, P., Saffrey, P., Bruce, A.W., Dillson, S.C., Chiang, K., Bonhoure, N.,
Koch, C.M., Bye, J., James, K., Foad, N.S., et al. (2010). Complex exon-intron
marking by histone modifications is not determined solely by nucleosome
distribution. PLoS ONE 5, e12339.
Dower, K., and Rosbash, M. (2002). T7 RNA polymerase-directed transcripts
are processed in yeast and link 30 end formation to mRNA nuclear export.
RNA 8, 686–697.
Eperon, L.P., Graham, I.R., Griffiths, A.D., and Eperon, I.C. (1988). Effects of
RNA secondary structure on alternative splicing of pre-mRNA: is folding
limited to a region behind the transcribing RNA polymerase? Cell 54, 393–401.
Fong, Y.W., and Zhou, Q. (2001). Stimulatory effect of splicing factors on tran-
scriptional elongation. Nature 414, 929–933.
Fox-Walsh, K.L., and Hertel, K.J. (2009). Splice-site pairing is an intrinsically
high fidelity process. Proc. Natl. Acad. Sci. USA 106, 1766–1771.
Gornemann, J., Kotovic, K.M., Hujer, K., and Neugebauer, K.M. (2005).
Cotranscriptional spliceosome assembly occurs in a stepwise fashion and
requires the cap binding complex. Mol. Cell 19, 53–63.
Gunderson, F.Q., and Johnson, T.L. (2009). Acetylation by the transcriptional
coactivator Gcn5 plays a novel role in co-transcriptional spliceosome
assembly. PLoS Genet. 5, e1000682.Han, S.P., Tang, Y.H., and Smith, R. (2010). Functional diversity of the hnRNPs:
past, present and perspectives. Biochem. J. 430, 379–392.
Hanamura, A., Caceres, J.F., Mayeda, A., Franza, B.R., and Krainer, A.R.
(1998). Regulated tissue-specific expression of antagonistic pre-mRNA
splicing factors. RNA 4, 430–444.
Hicks, M.J., Yang, C.R., Kotlajich, M.V., and Hertel, K.J. (2006). Linking
splicing to Pol II transcription stabilizes pre-mRNAs and influences splicing
patterns. PLoS Biol. 4, e147.
Hirose, Y., and Manley, J.L. (1998). RNA polymerase II is an essential mRNA
polyadenylation factor. Nature 395, 93–96.
Hodges, C., Bintu, L., Lubkowska, L., Kashlev, M., and Bustamante, C.
(2009a). Nucleosomal fluctuations govern the transcription dynamics of RNA
polymerase II. Science 325, 626–628.
Hodges, E., Smith, A.D., Kendall, J., Xuan, Z.Y., Ravi, K., Rooks, M., Zhang,
M.Q., Ye, K., Bhattacharjee, A., Brizuela, L., et al. (2009b). High definition
profiling of mammalian DNA methylation by array capture and single molecule
bisulfite sequencing. Genome Res. 19, 1593–1605.
Howe, K.J., Kane, C.M., and Ares, M., Jr. (2003). Perturbation of transcription
elongation influences the fidelity of internal exon inclusion in Saccharomyces
cerevisiae. RNA 9, 993–1006.
Kadener, S., Cramer, P., Nogues, G., Cazalla, D., de la Mata, M., Fededa, J.P.,
Werbajh, S.E., Srebrow, A., and Kornblihtt, A.R. (2001). Antagonistic effects of
T-Ag and VP16 reveal a role for RNA pol II elongation on alternative splicing.
EMBO J. 20, 5759–5768.
Kessler, O., Jiang, Y., and Chasin, L.A. (1993). Order of intron removal during
splicing of endogenous adenine phosphoribosyltransferase and dihydrofolate
reductase pre-mRNA. Mol. Cell. Biol. 13, 6211–6222.
Khanna, A., and Stamm, S. (2010). Regulation of alternative splicing by short
non-coding nuclear RNAs. RNA Biol. 7, 480–485.
Kishore, S., and Stamm, S. (2006). The snoRNA HBII-52 regulates alternative
splicing of the serotonin receptor 2C. Science 311, 230–232.
Kolasinska-Zwierz, P., Down, T., Latorre, I., Liu, T., Liu, X.S., and Ahringer, J.
(2009). Differential chromatin marking of introns and expressed exons by
H3K36me3. Nat. Genet. 41, 376–381.
Kornblihtt, A.R. (2005). Promoter usage and alternative splicing. Curr. Opin.
Cell Biol. 17, 262–268.
Kotovic, K.M., Lockshon, D., Boric, L., and Neugebauer, K.M. (2003). Cotran-
scriptional recruitment of the U1 snRNP to intron-containing genes in yeast.
Mol. Cell. Biol. 23, 5768–5779.
Lacadie, S.A., and Rosbash, M. (2005). Cotranscriptional spliceosome
assembly dynamics and the role of U1 snRNA:50ss base pairing in yeast.
Mol. Cell 19, 65–75.
Lazarev, D., and Manley, J.L. (2007). Concurrent splicing and transcription are
not sufficient to enhance splicing efficiency. RNA 13, 1546–1557.
LeMaire, M.F., and Thummel, C.S. (1990). Splicing precedes polyadenylation
during Drosophila E74A transcription. Mol. Cell. Biol. 10, 6059–6063.
Li, S.S., and Shogren-Knaak, M.A. (2009). The Gcn5 bromodomain of the
SAGA complex facilitates cooperative and cross-tail acetylation of nucleo-
somes. J. Biol. Chem. 284, 9411–9417.
Lin, S., Coutinho-Mansfield, G., Wang, D., Pandit, S., and Fu, X.D. (2008). The
splicing factor SC35 has an active role in transcriptional elongation. Nat.
Struct. Mol. Biol. 15, 819–826.
Listerman, I., Sapra, A.K., and Neugebauer, K.M. (2006). Cotranscriptional
coupling of splicing factor recruitment and precursor messenger RNA splicing
in mammalian cells. Nat. Struct. Mol. Biol. 13, 815–822.
Long, J.C., and Caceres, J.F. (2009). The SR protein family of splicing factors:
master regulators of gene expression. Biochem. J. 417, 15–27.
Loomis, R.J., Naoe, Y., Parker, J.B., Savic, V., Bozovsky, M.R., Macfarlan, T.,
Manley, J.L., and Chakravarti, D. (2009). Chromatin binding of SRp20 and
ASF/SF2 and dissociation frommitotic chromosomes is modulated by histone
H3 serine 10 phosphorylation. Mol. Cell 33, 450–461.Cell 144, January 7, 2011 ª2011 Elsevier Inc. 25
Luco, R.F., Pan, Q., Tominaga, K., Blencowe, B.J., Pereira-Smith, O.M., and
Misteli, T. (2010). Regulation of alternative splicing by histone modifications.
Science 327, 996–1000.
Maniatis, T., and Reed, R. (2002). An extensive network of coupling among
gene expression machines. Nature 416, 499–506.
Martinez, E., Palhan, V.B., Tjernberg, A., Lymar, E.S., Gamper, A.M., Kundu,
T.K., Chait, B.T., and Roeder, R.G. (2001). Human STAGA complex is a chro-
matin-acetylating transcription coactivator that interacts with pre-mRNA
splicingandDNAdamage-binding factors in vivo.Mol.Cell. Biol.21, 6782–6795.
Marzluff, W.F., Wagner, E.J., and Duronio, R.J. (2008). Metabolism and regu-
lation of canonical histone mRNAs: life without a poly(A) tail. Nat. Rev. Genet.
9, 843–854.
Mavrich, T.N., Ioshikhes, I.P., Venters, B.J., Jiang, C., Tomsho, L.P., Qi, J.,
Schuster, S.C., Albert, I., and Pugh, B.F. (2008). A barrier nucleosome model
for statistical positioning of nucleosomes throughout the yeast genome.
Genome Res. 18, 1073–1083.
McCracken, S., Fong, N., Rosonina, E., Yankulov, K., Brothers, G., Siderovski,
D., Hessel, A., Foster, S., Shuman, S., and Bentley, D.L. (1997a). 50-Capping
enzymes are targeted to pre-mRNA by binding to the phosphorylated car-
boxy-terminal domain of RNA polymerase II. Genes Dev. 11, 3306–3318.
McCracken, S., Fong, N., Yankulov, K., Ballantyne, S., Pan, G., Greenblatt, J.,
Patterson, S.D., Wickens, M., and Bentley, D.L. (1997b). The C-terminal
domain of RNA polymerase II couples mRNA processing to transcription.
Nature 385, 357–361.
McCracken, S., Rosonina, E., Fong, N., Sikes, M., Beyer, A., O’Hare, K., Shu-
man, S., and Bentley, D. (1998). Role of RNA polymerase II carboxy-terminal
domain in coordinating transcription with RNA processing. Cold Spring
Harb. Symp. Quant. Biol. 63, 301–309.
Meissner, A., Mikkelsen, T.S., Gu, H.C., Wernig, M., Hanna, J., Sivachenko, A.,
Zhang, X.L., Bernstein, B.E., Nusbaum, C., Jaffe, D.B., et al. (2008). Genome-
scale DNA methylation maps of pluripotent and differentiated cells. Nature
454, 766–770.
Misteli, T., and Spector, D.L. (1999). RNA polymerase II targets pre-mRNA
splicing factors to transcription sites in vivo. Mol. Cell 3, 697–705.
Moore, M.J., and Proudfoot, N.J. (2009). Pre-mRNA processing reaches back
to transcription and ahead to translation. Cell 136, 688–700.
Mun˜oz,M.J., Perez Santangelo, M.S., Paronetto,M.P., de laMata, M., Pelisch,
F., Boireau, S., Glover-Cutter, K., Ben-Dov, C., Blaustein, M., Lozano, J.J.,
et al. (2009). DNA damage regulates alternative splicing through inhibition of
RNA polymerase II elongation. Cell 137, 708–720.
Nahkuri, S., Taft, R.J., andMattick, J.S. (2009). Nucleosomes are preferentially
positioned at exons in somatic and sperm cells. Cell Cycle 8, 3420–3424.
Nogue´s, G., Kadener, S., Cramer, P., Bentley, D., and Kornblihtt, A.R. (2002).
Transcriptional activators differ in their abilities to control alternative splicing.
J. Biol. Chem. 277, 43110–43114.
Ohkura, N., Takahashi, M., Yaguchi, H., Nagamura, Y., and Tsukada, T. (2005).
Coactivator-associated arginine methyltransferase 1, CARM1, affects pre-
mRNAsplicing in an isoform-specificmanner. J. Biol. Chem.280, 28927–28935.
O’Keefe, R.T., Mayeda, A., Sadowski, C.L., Krainer, A.R., and Specotr, D.L.
(1994). Disruption of pre-mRNA splicing in vivo results in reorganization of
splicing factors. J. Cell Biol. 124, 249–260.
Pagani, F., Stuani, C., Zuccato, E., Kornblihtt, A.R., and Baralle, F.E. (2003).
Promoter architecture modulates CFTR exon 9 skipping. J. Biol. Chem. 278,
1511–1517.
Pan, Q., Shai, O., Lee, L.J., Frey, B.J., and Blencowe, B.J. (2008). Deep
surveying of alternative splicing complexity in the human transcriptome by
high-throughput sequencing. Nat. Genet. 40, 1413–1415.
Pandya-Jones, A., and Black, D.L. (2009). Co-transcriptional splicing of
constitutive and alternative exons. RNA 15, 1896–1908.
Piacentini, L., Fanti, L., Negri, R., Del Vescovo, V., Fatica, A., Altieri, F., and
Pimpinelli, S. (2009). Heterochromatin protein 1 (HP1a) positively regulates26 Cell 144, January 7, 2011 ª2011 Elsevier Inc.euchromatic gene expression through RNA transcript association and interac-
tion with hnRNPs in Drosophila. PLoS Genet. 5, e1000670.
Ponts, N., Yang, J.F., Chung, D.W.D., Prudhomme, J., Girke, T., Horrocks, P.,
and Le Roch, K.G. (2008). Deciphering the ubiquitin-mediated pathway in api-
complexan parasites: A potential strategy to interfere with parasite virulence.
PLoS ONE 3, e2386.
Pray-Grant, M.G., Daniel, J.A., Schieltz, D., Yates, J.R., 3rd, and Grant, P.A.
(2005). Chd1 chromodomain links histone H3 methylation with SAGA- and
SLIK-dependent acetylation. Nature 433, 434–438.
Roberts, G.C., Gooding, C., Mak, H.Y., Proudfoot, N.J., and Smith, C.W.
(1998). Co-transcriptional commitment to alternative splice site selection. Nu-
cleic Acids Res. 26, 5568–5572.
Sapra, A.K., Anko, M.L., Grishina, I., Lorenz, M., Pabis, M., Poser, I., Rollins, J.,
Weiland, E.M., and Neugebauer, K.M. (2009). SR protein family members
display diverse activities in the formation of nascent and mature mRNPs
in vivo. Mol. Cell 34, 179–190.
Schor, I.E., Rascovan, N., Pelisch, F., Allo, M., and Kornblihtt, A.R. (2009).
Neuronal cell depolarization induces intragenic chromatin modifications affecting
NCAM alternative splicing. Proc. Natl. Acad. Sci. USA 106, 4325–4330.
Schwartz, S., Meshorer, E., and Ast, G. (2009). Chromatin organization marks
exon-intron structure. Nat. Struct. Mol. Biol. 16, 990–995.
Sims, R.J., Millhouse, S., Chen, C.F., Lewis, B.A., Erdjument-Bromage, H.,
Tempst, P., Manley, J.L., and Reinberg, D. (2007). Recognition of trimethylated
histone h3 lysine 4 facilitates the recruitment of transcription postinitiation
factors and pre-mRNA splicing. Mol. Cell 28, 665–676.
Sisodia, S.S., Sollner-Webb, B., and Cleveland, D.W. (1987). Specificity of
RNA maturation pathways: RNAs transcribed by RNA polymerase III are not
substrates for splicing or polyadenylation. Mol. Cell. Biol. 7, 3602–3612.
Smale, S.T., and Tjian, R. (1985). Transcription of herpes simplex virus tk
sequences under the control of wild-type and mutant human RNA polymerase
I promoters. Mol. Cell. Biol. 5, 352–362.
Spies, N., Nielsen, C.B., Padgett, R.A., and Burge, C.B. (2009). Biased chro-
matin signatures around polyadenylation sites and exons. Mol. Cell 36,
245–254.
Tardiff, D.F., Lacadie, S.A., and Rosbash, M. (2006). A genome-wide analysis
indicates that yeast pre-mRNA splicing is predominantly posttranscriptional.
Mol. Cell 24, 917–929.
Tennyson, C.N., Klamut, H.J., andWorton, R.G. (1995). The human dystrophin
gene requires 16 hours to be transcribed and is cotranscriptionally spliced.
Nat. Genet. 9, 184–190.
Tilgner, H., Nikolaou, C., Althammer, S., Sammeth,M., Beato,M., Valcarcel, J.,
and Guigo, R. (2009). Nucleosome positioning as a determinant of exon
recognition. Nat. Struct. Mol. Biol. 16, 996–1001.
Tyagi, A., Ryme, J., Brodin, D., Farrants, A.K.O., and Visa, N. (2009). SWI/SNF
associates with nascent pre-mRNPs and regulates alternative pre-mRNA pro-
cessing. PLoS Genet. 5, e1000470.
Ule, J., Ule, A., Spencer, J., Williams, A., Hu, J.S., Cline, M., Wang, H., Clark,
T., Fraser, C., Ruggiu, M., et al. (2005). Nova regulates brain-specific splicing
to shape the synapse. Nat. Genet. 37, 844–852.
Wagner, E.J., Burch, B.D., Godfrey, A.C., Salzler, H.R., Duronio, R.J., andMar-
zluff, W.F. (2007). A genome-wide RNA interference screen reveals that variant
histones, are necessary for replication-dependent histone pre-mRNA pro-
cessing. Mol. Cell 28, 692–699.
Wang, E.T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., King-
smore, S.F., Schroth, G.P., and Burge, C.B. (2008). Alternative isoform regula-
tion in human tissue transcriptomes. Nature 456, 470–476.
Xiao, T.J., Hall, H., Kizer, K.O., Shibata, Y., Hall, M.C., Borchers, C.H., and
Strahl, B.D. (2003). Phosphorylation of RNA polymerase II CTD regulates H3
methylation in yeast. Genes Dev. 17, 654–663.
Zofall, M., Fischer, T., Zhang, K., Zhou, M., Cui, B.W., Veenstra, T.D., and
Grewal, S.I.S. (2009). Histone H2A.Z cooperates with RNAi and heterochro-
matin factors to suppress antisense RNAs. Nature 461, 419–422.
